Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

Hong Kong-listed Sino Biopharmaceutical said on Wednesday it has granted AstraZeneca the rights to develop a drug designed to treat chronic respiratory diseases outside China for total payments of up to $1.9 billion.

• Under the deal, AstraZeneca gets an exclusive license to develop, manufacture and commercialize the drug - TQC3721 - outside China, with additional exclusive global rights for certain future development programs.

• Designed to open airways and fight inflammation at the same time, TQC3721 aims to improve lung function and reduce severe flare-ups for patients with long-term respiratory conditions, Sino Biopharmaceutical said.

• The Hong Kong-listed firm is eligible to receive an upfront payment of $200 million, with additional development and other milestone payments.

(Reporting by Sneha Kumar in Bengaluru; Editing by Jonathan Ananda)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published July 7, 2026 at 7:18 PM.